RaDVaC Data Explorer
Antiviral database
Virus Taxonomy
← Back to Dashboard
Symtuza
Protease inhibitor + booster + 2x NRTI
Constituent drugs (4)
Darunavir
Loading structure...
3D not available
Cobicistat
Loading structure...
3D not available
Emtricitabine
Loading structure...
3D not available
Tenofovir Alafenamide
Loading structure...
3D not available
Chemical Identifiers
ClinicalTrials.gov
PubMed
Clinical Development by Virus
1
Human immunodeficiency virus 1
HIV-1
Target: Viral protease + RT
Approved (other)
Preclinical
Phase 2
positive
Phase 3
positive
Approved
Japan
Approval ref (pmda.go.jp)
PMDA approved Jun. 18, 2019
fixed-dose combination of Darunavir, Cobicistat, Emtricitabine, Tenofovir alafenamide.